Furthermore, we confirmed that SFXN3 promotes DNA methylation in non-M3 AML patients at transcription start sites (TSS), which clustered in multiple vital cell functions and accompanied by mutations in DNMT3A and NPM1, indicating a potential biomarker for evaluating tumor methylation enrichment and predicting the prognosis of the disease. The gene discussed is SFXN3; the disease is acute myeloid leukemia.